GSK myeloma combo reduced disease progression, death risk by nearly 50% versus standard of care
- DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS)
- Median PFS not yet reached at 21.8 months median follow-up versus 12.7 months in bortezomib combination
- Second trial to show robust efficacy for a belantamab mafodotin combination versus a standard of care in second line and later relapsed/refractory multiple myeloma
- Results simultaneously published in the New England Journal of Medicine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.